Aspen Neuroscience Announces $147.5 Million Series B Financing, led by GV, LYFE Capital and Revelation Partners
Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease, announced the
- 09 05 2022
- |